pharmaphorum June 17, 2022
Walgreens is the latest US retail pharmacy giant to have a go at disrupting the clinical trials industry, with the launch of a new business unit that will tap into its reserve of patient data, as well as the ability to recruit patients across its retail network.
The company says it plans to use a “flexible” model, drawing on both decentralised trial (DCT) and conventional site-based models via its Health Corner and Village Medical outlets at various Walgreens locations across the US.
The move follows in the footsteps of rival chain CVS, which launched its clinical trials services business last year. Walgreens’ approach is very similar to CVS’ focus on DCT and hybrid trial, as well as use of its...